MRK logo

MRKMerck & Co Inc

$122.00
$1.67
(1.40%)
Today
Closed $120.76
$1.24
(1.03%)
After Hours
Updated: 05:53 PM EDT
EarningsAug 4
Mkt Cap$294.13B
Vol13.18M
News
all
press releases
Pharma and Biotech M&A Boom Accelerates as Companies Expand Pipelines
Pharma and biotech dealmaking is surging in 2026 as companies pursue acquisitions to expand pipelines, strengthen portfolios and drive growth.
Zacks
News Placeholder
More News
News Placeholder
The Zacks Analyst Blog Highlights Merck, The Southern, Lumentum and Peoples Bancorp of North Carolina
Merck, Southern Company, Lumentum and Peoples Bancorp of North Carolina are highlighted for growth drivers, performance and key risks.
Zacks
News Placeholder
Investors Heavily Search Merck & Co., Inc. (MRK): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Merck (MRK). This makes it worthwhile to examine what the stock has in store.
Zacks
News Placeholder
Is PAHC Undervalued at 10x Earnings vs Peers?
Phibro trades near 10x forward earnings vs higher peer multiples as strong Q3 beat, margin gains and 2026 guidance support a modest upside case.
Zacks
News Placeholder
Merck Animal Health To Acquire TARGAN To Expand Poultry Technology Portfolio
(RTTNews) - Merck Animal Health, a division of Merck & Co. (MRK), on Thursday announced a definitive agreement to acquire TARGAN, a privately held developer of biodevice solutions for the poultry industry, for undisclosed consideration...
Nasdaq News: Markets
News Placeholder
Merck Animal Health to Acquire TARGAN
Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced that it has signed a definitive agreement to acquire TARGAN, a privately held innovator in developing and commercializing biodevice...
Business Wire
News Placeholder
Top Research Reports for Merck, Southern Company & Lumentum
Merck, Southern Company and Lumentum lead Zacks' featured research reports as growth drivers, expansion plans and key risks shape outlooks.
Zacks
News Placeholder
Can Gilead Sciences HIV Franchise Drive Long-Term Growth?
Gilead's HIV franchise gains momentum as Biktarvy and Descovy drive growth, Yeztugo outlook rises, and late-stage pipeline advances.
Zacks
News Placeholder
Merck Stock Moves Above 50-Day SMA: Assessing Its Investment Case
MRK has reclaimed its 50-day SMA while holding above its 200-day trendline, backed by Keytruda growth, pipeline advances and recent deals.
Zacks
News Placeholder
Gilead, Merck Report Positive Phase III HIV Study Data, End NSCLC Study
Gilead and Merck report positive phase III results for once-weekly HIV regimen islatravir/lenacapavir, while ending a lung cancer study.
Zacks
<
1
2
...
>

Advertisement|Remove ads.